HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

Project description

Therapeutic proteins to treat nerve pain and hearing loss

Current treatments for nerve (neuropathic) pain do not sufficiently treat pain symptoms. Most have serious side effects. Existing treatment options for hearing aids and cochlear implants are limited, with no approved pharmaceutical therapies. The EU-funded Sense21 project proposes novel therapeutics called HB-086 and HB-097 to treat neuropathic pain and hearing disorders. Research shows these two molecules have unique actions on sensory nerve cells and their surrounding support cells. Preclinical data reveal that HB-086 provides relief from neuropathic pain, while HB 097 preserves the sense of hearing. They could serve as novel treatment approaches and bring about a radical change in medical treatment and in the prevention of severe chronic conditions.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › biochemistry › biomolecules › proteins

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
• HORIZON.3.1.2 - The Accelerator

Topic(s)

• HORIZON-EIC-2021-ACCELERATOROPEN-01 - EIC Accelerator Open 2021

Call for proposal

HORIZON-EIC-2021-ACCELERATOROPEN-01

See other projects for this call

Funding Scheme

HORIZON-AG - HORIZON Action Grant Budget-Based

Coordinator

HOBA THERAPEUTICS APS

Net EU contribution

€ 2 325 312,50

Address

Ole Maaloes Vej 3
2200 Copenhagen
Denmark

Region

Danmark › Hovedstaden › Byen København

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 996 562,50